Skip to main content

Avelumab, Talazoparib, and Axitinib in Treating Patients with MSS, MSI-H, and POLE-Mutated Recurrent or Persistent Endometrial Cancer

Trial Status: Active

This phase II trial studies how well avelumab together with talazoparib or axitinib work in treating patients with microsatellite stable (MSS), high frequency microsatellite instability (MSI-H), and polymerase e (POLE)-mutated endometrial cancer that has come back (recurrent) or does not go to remission despite treatment (persistent). Immunotherapy with monoclonal antibodies, such as avelumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Talazoparib and axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving avelumab together with talazoparib or axitinib may work better in treating MSS endometrial cancer compared to avelumab alone.

Inclusion Criteria

  • Participants must be classified into one of the following cohorts of recurrent or persistent endometrial cancer of any histology: * The MSI/POLE cohort includes endometrial cancers that are: MSI-H as determined by immunohistochemical complete loss of expression (absence of nuclear immunoreactivity) of at least one of the mismatch repair genes MSH2, MSH6, MLH1 and PMS2; this test is now done routinely for every newly diagnosed endometrial cancer patient in most centers in the United States (US); AND/OR: POLE-mutated, i.e. endometrial cancers known to harbor mutations in the exonuclease domain (amino acid residues 268–471) of polymerase e (POLE) as determined by targeted sequencing or other next generation sequencing assay; any Clinical Laboratory Improvement Amendments (CLIA)-approved genomic test documenting mutations in the exonuclease domain of POLE gene (amino acid residues 268–471) in the tumor will be accepted as proof of presence of POLE mutations and will lead to classification into this patient cohort * The MSS cohorts include: endometrial cancers that are MSS as determined by normal immunohistochemical nuclear expression of all the mismatch repair genes MSH2, MSH6, MLH1 and PMS2; tumors which have not been sequenced for POLE mutations (i.e. their POLE mutations status is unknown) but are MSS, will be included in this cohort
  • All patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be > 15 mm in short axis when measured by CT or MRI
  • There is no upper limit of prior therapies but patients must have had one prior chemotherapeutic regimen for management of endometrial carcinoma; initial treatment may include chemotherapy, chemotherapy and radiation therapy, and/or consolidation/maintenance therapy; any platinum based chemotherapy (single agent platinum or any platinum doublet) administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a systemic chemotherapy regimen; furthermore, patients who have only received chemotherapy in the adjuvant setting will be eligible for the study
  • Prior hormonal therapy is allowed (no washout period is required after hormonal therapy)
  • Patients must NOT have received any class of drugs targeted to the PD-1/PD-L1 pathway
  • Patients must NOT have received any prior poly adenosine phosphate ribose polymerase (PARP) inhibitor therapy (for patients being considered for the avelumab/talazoparib cohort only)
  • Patients must NOT have received prior axitinib (for patients being considered for the avelumab/axitinib cohort only)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Availability of a formalin fixed paraffin embedded (FFPE) block of cancer tissue OR 15 unstained 5-micron slides from the original surgery or biopsy or from a biopsy of recurrent disease
  • Absolute neutrophil count > 1,500/mcL
  • Platelets > 100,000/mcL
  • Hemoglobin >= 9 g/dL
  • Total bilirubin within normal institutional limits
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine Aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal
  • Creatinine =< institutional upper limit of normal OR creatinine clearance >= 30 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal * Creatinine clearance should be estimated according to the Cockcroft-Gault formula * NOTE: patients with moderate renal impairment (defined as an estimated creatinine clearance of 30-59 mL/min) will receive a reduced starting dose of talazoparib at 0.75 mg PO QD
  • Participant must not be pregnant or breastfeeding given that avelumab is an agent with unknown effects in pregnancy and breastfeeding and the potential for teratogenesis; females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or post-menopausal (defined as >= 12 months with no menses without an alternative medical cause); serum pregnancy test (for females of childbearing potential) negative at screening
  • The effects of avelumab on the developing human fetus are unknown; for this reason and because some immunomodulatory agents are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 30 days after last avelumab treatment administration; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Toxicities of prior therapy (excepting alopecia and sensory neuropathy) should be resolved to < grade 2 per the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4; all appropriate treatment areas should have access to a copy of the CTCAE version 4. A copy of the CTCAE version 4 can be downloaded from the CTEP website at: http://ctep.cancer.gov
  • Ability to understand and the willingness to sign a written informed consent document
  • AVELUMAB/AXITINIB COHORT: Participants must have adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as systolic BP that must be =<140 mmHg and diastolic BP that must be =< 90 mmHg on two separate BP readings taken at least 1 hour apart at screening
  • AVELUMAB/AXITINIB COHORT: Participants must have left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) as assessed by either multigated acquisition (MUGA) scan or echocardiogram (ECHO)

Exclusion Criteria

  • Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
  • Participants who are receiving any other investigational agents
  • Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
  • History of allergic reactions attributed to avelumab or any component in its formulations, or compounds of similar chemical or biologic composition to avelumab; known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 NCI CTCAE version [v] 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
  • Participants with a history of treatment with an anti-PD-1, anti-PD-L1, anti-CTLA-4 or other investigational agents that target immune checkpoint inhibitors
  • Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness, which may compromise the efficacy of immunostimulatory therapy
  • Positive test for hepatitis B virus (HBV) surface antigen
  • Positive hepatitis C antibody and positive confirmatory hepatitis C virus (HCV) ribonucleic acid (RNA) test; the confirmatory HCV RNA test is not required if the HCV antibody is negative; if hepatitis C antibody is positive, the confirmatory HCV RNA test should be done and if it is negative, then participants are eligible
  • Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses =< 10 mg or 10 mg equivalent prednisone per day
  • Active infection requiring systemic therapy
  • Current or prior use of immunosuppressive medication within 7 days prior to enrollment with the following exceptions to this exclusion criterion: * Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection) * Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent * Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
  • Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent; patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible
  • Prior organ transplantation including allogeneic stem-cell transplantation
  • Severe gastrointestinal conditions such as clinical or radiological evidence of bowel obstruction within 4 weeks prior to study entry, uncontrolled diarrhea in the last 4 weeks prior to enrollment, or history of inflammatory bowel disease
  • Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication
  • Known alcohol or drug abuse
  • Individuals with a history of a different malignancy are ineligible except for the following circumstances: individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years or if they are deemed by the investigator to be at low risk for recurrence of that malignancy; individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: breast cancer in situ, cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin
  • All other significant diseases (for example, inflammatory bowel disease, uncontrolled asthma), which, in the opinion of the investigator, might impair the subject’s tolerance of trial treatment
  • Any psychiatric condition that would prohibit the understanding or rendering of informed consent
  • Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
  • Patients may not use natural herbal products or other “folk remedies” while participating in this study; herbal medications include, but are not limited to St. John’s wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng
  • AVELUMAB/AXITINIB COHORT: Participants having > 1+ proteinuria on urinalysis or urine protein to creatinine ratio (UPCR) > 1 will undergo a 24-hour urine collection for quantitative assessment of proteinuria; participants with urine protein > 1 g/24-hours will be ineligible
  • AVELUMAB/AXITINIB COHORT: Participants with concern for bowel or serosal involvement will be ineligible, due to the risk of perforation or fistulization with anti-angiogenic agents.
  • AVELUMAB/AXITINIB COHORT: Participants will be ineligible if they have active gastrointestinal bleeding, as evidenced by clinically significant hematemesis, hematochezia, or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy
  • AVELUMAB/AXITINIB COHORT: Participants will be ineligible if using anticoagulant therapy with oral vitamin K antagonists, novel oral anticoagulants (NOACs), or direct oral anticoagulants (DOACs), inclusive of direct thrombin inhibitors and direct factor Xa inhibitors; therapeutic use of low molecular weight heparin is allowed; low dose heparin required for maintenance of patency of central venous access devices are allowed
  • AVELUMAB/AXITINIB COHORT: Grade >= 3 hemorrhage within 4 weeks preceding cycle 1 day 1 treatment
  • AVELUMAB/AXITINIB COHORT: Ongoing cardiac dysrhythmias of CTCAE grade >= 2, or prolongation of the corrected QT (QTc) interval to > 500 msec
  • AVELUMAB/AXITINIB COHORT: Current use or anticipated need for treatment with drugs or foods that are known to be either: * Strong CYP3A4/5 inhibitors, including administration within 10 days prior to cycle 1 day 1 treatment, including but not limited to grapefruit juice, grapefruit-related fruits (Seville oranges, pomelos), ketoconazole, miconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, amprenavir, fosamprenavir nefazodone, lopinavir, troleandomycin, mibefradil, conivaptan. The topical use of these medications is allowed if systemic absorption is considered minimal * Strong CYP3A4/5 inducers, including administration within 10 days prior to cycle 1 day 1 treatment, including but not limited to phenobarbital, rifampin, phenytoin, carbamazepine, rifabutin, rifapentine, clevidipine, St. John’s wort

Illinois

Chicago
University of Chicago Comprehensive Cancer Center
Status: ACTIVE
Contact: Gini F. Fleming
Phone: 773-702-6712

Massachusetts

Boston
Beth Israel Deaconess Medical Center
Status: ACTIVE
Contact: Mary Kathleen Buss
Phone: 617-667-4820
Brigham and Women's Hospital
Status: ACTIVE
Contact: Panagiotis A. Konstantinopoulos
Phone: 617-632-5269
Dana-Farber Cancer Institute
Status: ACTIVE
Contact: Panagiotis A. Konstantinopoulos
Phone: 617-632-5269
Massachusetts General Hospital Cancer Center
Status: ACTIVE
Contact: Richard Thomas Penson
Phone: 617-724-4800

PRIMARY OBJECTIVES:

I. To assess the activity of avelumab in patients with recurrent or persistent endometrial cancer classified by MSI/POLE and MSS genomic cohorts as well as the activity of avelumab plus talazoparib in patients with recurrent MSS endometrial cancers as determined by the frequency of patients who survive progression-free for at least 6 months (PFS6) after initiating therapy or have objective tumor response.

II.To assess the clinical activity of combination avelumab/axitinib in patients with MSS recurrent or persistent endometrial cancer, as determined by the frequency of patients who survive progression-free for at least 6 months (PFS6).

III. To assess the clinical activity of combination avelumab/axitinib in patients with MSS recurrent or persistent endometrial cancer, as determined by the objective response rate (ORR) measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

SECONDARY OBJECTIVES:

I. To determine the duration of progression-free survival and overall survival for each cohort.

II. To determine the nature and degree of toxicity of avelumab or avelumab/talazoparib for each cohort as classified by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

III. To determine immune-related objective response rate for each cohort.

IV. Immune-related progression-free survival (irPFS) rate for each cohort defined as time from cohort assignment to death or to immune-related progression of disease (irPD).

V. To assess the clinical activity of combination avelumab/axitinib as measured by median progression-free survival (PFS) and median overall survival (OS).

VI. To assess the clinical activity of combination avelumab/axitinib as measured by the immune-related ORR, as measured by immune-related (ir)RECIST criteria.

VII.To assess the clinical activity of combination avelumab/axitinib as measured by the immune-related PFS (irPFS).

VIII. To determine the safety and toxicity of combination avelumab/axitinib, as classified by the CTCAE version (v) 4.1.

EXPLORATORY OBJECTIVES:

I. Assessment of CD3+ tumor infiltrating lymphocytes (TILs) and circulating lymphocytes, CD8+ TILs, CD8+/CD4+FOXP3+ TIL ratio, CD137+CD8+ TILs, D137+CD8+/CD4+FOXP3+ TIL ratio and correlation with response.

II. Assessment of myeloid, stromal and other immunoactive cell types from blood, tissue and fluid samples and correlation with response.

III. Assessment of the expression pre-, during, and at time of progression of immune checkpoints including TIM-3, LAG-3, CTLA-4, PD-L2, PD-L1, PD-1, IDO and correlation with response.

IV. Whole exome sequencing (WES) for specific deoxyribonucleic acid (DNA) gene repair mutations and neoantigen assessment as well as for single nucleotide polymorphisms (SNPs) in immunologically relevant genes and correlation with response.

V. Presence of anti-avelumab antibodies and correlation with response.

OUTLINE: Patients are assigned to 1 of 4 cohorts.

COHORT I (MSI/POLE): Patients receive avelumab intravenously (IV) over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.

COHORT II (MSS): Patients receive avelumab IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.

COHORT III (MSS): Patients receive avelumab IV over 1 hour on days 1 and 15 and talazoparib orally (PO) once daily (QD). Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.

COHORT IV (MSS): Patients receive avelumab IV over 1 hour on days 1 and 15 and axitinib PO twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.

After completion of study treatment, patients are followed up for 90 days and then every 6 months for 3 years.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Dana-Farber Harvard Cancer Center

Principal Investigator
Panagiotis A. Konstantinopoulos

  • Primary ID 16-322
  • Secondary IDs NCI-2016-01864
  • Clinicaltrials.gov ID NCT02912572